Novel drug delivery technologies for value-added medicines

5 Mar 2018

Licensing agreement enables Recipharm to co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.

Recipharm has signed a licensing agreement with Altus Formulation, a Canadian drug development company, to allow its customers to access new drug delivery technologies and products.

Novel drug delivery technologies for value-added medicines

Under the terms of the agreement, Recipharm will co-develop new value-added medicines for its customers utilising Altus’ patented Intellitab and Flexitab drug delivery technologies.

Intellitab is a novel misuse and abuse-deterrent technology that mitigates the dangers of over-exposure to opioids that can occur due to inadvertent or deliberate tampering with immediate release or extended release narcotics. Intellitab tablets are hardened to resist cutting, crushing and chewing, common methods to accelerate drug release, and spontaneously form hard, stable gels in a range of solvents to deter injection. To date, the technology has been used for the development of both narcotic and stimulant products for sale in North America.

Flexitab is a commercially validated extended-release technology enabling alcohol resistant tablets that maintain their performance after breaking to generate bio-equivalent lower strength tablets. As a result, Flexitab tablets may be broken with no risk of dose dumping or loss of controlled release, eliminating the need for multiple tablets for patients whose regime requires the ability to titrate to effect. The technology can be used to generate novel enhanced generic tablets and to increase the value of existing non-breakable extended-release products.

”This collaboration is an exciting step for Recipharm, enabling us to bring innovative drug delivery technologies to our customers and ultimately develop novel, safer and cost-effective new products. We look forward to working with Altus to increase the use of its technologies in Europe”, says Bernard Pluta, President Development Services at Recipharm.

”We are delighted to enter into this agreement and look forward to co-developing a range of patent protected, label differentiated new products with Recipharm and its customers”, says Damon Smith, CEO of Altus.

Read More

Related tags

Market News

Related news

BIA Separations expands with new upstream processing facility

BIA Separations expands with new upstream processing facility

20 Sep 2018

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Recipharm connects to European Hub for serialisation compliance

Recipharm connects to European Hub for serialisation compliance

18 Sep 2018

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

Read more 
Bosch to unveil new laboratory device for continuous manufacturing

Bosch to unveil new laboratory device for continuous manufacturing

18 Sep 2018

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Read more 
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

17 Sep 2018

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Read more 
Cambrex expands manufacturing footprint with acquisition

Cambrex expands manufacturing footprint with acquisition

16 Sep 2018

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Read more 
NMPA approves fruquintinib capsules for metastatic colorectal cancer

NMPA approves fruquintinib capsules for metastatic colorectal cancer

13 Sep 2018

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

Read more 
Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more